Abstract: The present invention pertains to the use of conjugated fumonisin (FUM) in a method to protect an animal against FUM induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, intestinal damage, liver damage and kidney damage as a result of the ingestion of FUM.

Abstract: The present invention pertains to the use of conjugated zearalenone (ZEA) in a method to protect an animal against ZEA induced mycotoxicosis, in particular to protect against decreased weight gain, kidney damage, liver damage and damage to a reproductive organ.

Abstract: The present invention pertains to the use of conjugated T-2 toxin (T2) in a method to protect an animal against T2 induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, intestinal damage, skin damage and snout damage, thus one or more of these signs of mycotoxicosis induced by T2 as a result of the ingestion of T2.

Abstract: The present invention pertains to the use of conjugated aflatoxin (AFB) in a method to protect an animal against AFB induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, immune suppression, icterus, hemorrhagic enteritis as a result of the ingestion of AFB.

Abstract: The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 (PCV2), non-replicating immunogen of Mycoplasma hyopneumoniae and conjugated deoxynivalenol (DON) for protecting swine against an infection with porcine circo virus type 2, an infection with Mycoplasma hyopneumoniae and DON induced mycotoxicosis.

Abstract: The present invention relates to a method of vaccination. Specifically the invention regards to a prime-boost vaccination regimen for protecting a target animal against infection or disease caused by a virus, wherein the vaccination regimen comprises the administration to said target animal of a vaccine comprising a live attenuated form of said virus, followed by the administration to said target animal of a vaccine comprising an RP encoding one or more antigens from said virus.

Abstract: The present invention pertains to a vaccine comprising an ORF2 encoded protein of porcine circo virus 2 (PCV2) and a pharmaceutically acceptable carrier, for use in a method to protect a pig against an infection with porcine circo virus type 2 by administering the vaccine to the pig, wherein the vaccine comprises less than 20 ?g per dose of the ORF2 encoded protein, the protein being of a porcine circo virus of genotype 2b.

Abstract: The present invention relates to vaccination against animal pathogens using alphavirus-replicon RNA particles and oil adjuvants. To a vaccine, and a kit of parts comprising the replicon particles and the oil adjuvant. Also to methods and uses of making and using the vaccine and the components of the kit.

Abstract: The present invention pertains to a vaccine comprising an ORF2 encoded protein of porcine circo virus 2 (PCV2) and a pharmaceutically acceptable carrier, for use in a method to protect a pig against an infection with porcine circo virus type 2 by administering the vaccine to the pig, wherein the vaccine comprises less than 20 ?g per dose of the ORF2 encoded protein, the protein being of a porcine circo virus of genotype 2b.

Abstract: The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with Lawsonia intracellularis, the vaccine being in a form suitable for systemic administration.

Abstract: The present invention pertains to a vaccine comprising in combination non-live antigens of Lawsonia intracellularis, of Mycoplasma hyopneumniae and Porcine circo virus, and a pharmaceutically acceptable carrier. The invention also pertains to a kit comprising a first container having contained therein non-live antigens of Lawsonia intracellularis, one or more other containers having contained therein Mycoplasma hyopneumoniae and Porcine circo virus antigens and instructions for mixing the antigens of Lawsonia intracellularis, Mycoplasma hyopneumoniae, and Porcine circo virus to formulate one combination vaccine suitable for systemic vaccination.

Abstract: The present invention pertains to the use of Haemophilus parasuis bacteria of serotype 5 expressing an iron-restriction protein visible on a Western-blot when reacted with serum of a convalescent animal which has recovered from an infection by Haemophilus parasuis bacteria of serotype 4, the said protein not being visible on a Western-blot when Haemophilus parasuis bacteria of serotype 5 grown under iron-replete conditions, are reacted under the same conditions, in a vaccine to protect a subject animal against a disorder arising from Haemophilus parasuis serotype 4 bacteria.

Abstract: The present invention pertains to the use of Streptococcus suis antigens corresponding to Streptococcus suis bacteria of a predetermined serotype in the manufacture of a vaccine for administration to a sow or gilt, to protect a piglet through the intake of colostrum of the said sow or gilt, against a disorder arising from Streptococcus suis bacteria of a serotype other than the predetermined one. The invention also pertains to Streptococcus suis antigens for use in the manufacture of such a vaccine.

Abstract: The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with Lawsonia intracellularis, the vaccine being in a form suitable for systemic administration.

Abstract: The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with Lawsonia intracellularis, the vaccine being in a form suitable for systemic administration.

Abstract: The present invention pertains to a vaccine comprising in combination non-live antigens of Lawsonia intracellularis, of Mycoplasma hyopneumniae and Porcine circo virus, and a pharmaceutically acceptable carrier. The invention also pertains to a kit comprising a first container having contained therein non-live antigens of Lawsonia intracellularis, one or more other containers having contained therein Mycoplasma hyopneumoniae and Porcine circo virus antigens and instructions for mixing the antigens of Lawsonia intracellularis, Mycoplasma hyopneumoniae, and Porcine circo virus to formulate one combination vaccine suitable for systemic vaccination.

Abstract: The present invention pertains to the use of Haemophilus parasuis bacteria of serotype 5 expressing an iron-restriction protein visible on a Western-blot when reacted with serum of a convalescent animal which has recovered from an infection by Haemophilus parasuis bacteria of serotype 4, the said protein not being visible on a Western-blot when Haemophilus parasuis bacteria of serotype 5 grown under iron-replete conditions, are reacted under the same conditions, in a vaccine to protect a subject animal against a disorder arising from Haemophilus parasuis serotype 4 bacteria.

Abstract: The present invention pertains to the use of Streptococcus suis antigens corresponding to Streptococcus suis bacteria of a predetermined serotype in the manufacture of a vaccine for administration to a sow or gilt, to protect a piglet through the intake of colostrum of the said sow or gilt, against a disorder arising from Streptococcus suis bacteria of a serotype other than the predetermined one. The invention also pertains to Streptococcus suis antigens for use in the manufacture of such a vaccine.

Abstract: The present invention relates to the use of bacteria of the species Streptococcus phocae for the manufacture of a vaccine, to methods for the production of such vaccines, to bacteria of the species Streptococcus phocae for use in a vaccine and to methods for the combating of Streptococcus phocae infection in fish.

Abstract: The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with Lawsonia intracellularis, the vaccine being in a form suitable for systemic administration.